https://pittplusme.org/study/1980
Janssen Atopic Dermatitis Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have atopic dermatitis (also called eczema)? You may be able to participate in a study to see if a study drug called bermekimab is safe and useful for treating patients with moderate to severe atopic dermatitis. Participation in this study will last up to 40 weeks and includes up to 36 visits. Compensation is provided.
IRB: 8546-LKFerris
- A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants with Moderate to Severe Atopic Dermatitis
AGE:
18 and up
DURATION:
Up to 40 weeks
VISITS:
Up to 36 visits
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$50 per completed study visit
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.